Hidradenitis Suppurativa
Conditions
Keywords
Bimekizumab, HS, Hidradenitis Suppurativa
Brief summary
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
Interventions
DRUGBimekizumab
Bimekizumab will be administered at pre-specified timepoints.
Sponsors
UCB Biopharma SRL
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
9 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Study participant must be 12 to \<18 years of age at the time of informed consent/assent, at Tanner stage 2 or more, for the first 8 participants only, followed by also including participants ≥9 to \<18 years of age at Tanner stage 2 or more. * Study participant must have a diagnosis of HS for at least 6 months prior to the Baseline Visit. * Study participant must have moderate to severe HS, defined as a total of ≥5 inflammatory lesions (ie, the sum of abscesses and inflammatory nodules), as assessed at both the Screening and Baseline Visits. * Study participant must have HS lesions present in at least 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or III, as assessed at both the Screening and Baseline Visits. * Study participant must have had a history of inadequate response to a course of a systemic antibiotic for treatment of HS * Study participant must weigh ≥30kg at the Screening Visit.
Exclusion criteria
* Study participant has a draining tunnel count of \>20 at either the Screening or Baseline Visits. * Study participant has experienced primary failure (no response within 12 weeks) to 1 or more IL 17 biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR primary failure to more than 1 biologic response modifier other than an IL-17 biologic response modifier. * Study participant has previously participated in this study or has received previous therapy with bimekizumab. * Study participant has a history of IBD or symptoms suggestive of IBD. * History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated * Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections) * Study participant has received drugs outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments * Study participant has the presence of active suicidal ideation, or positive suicide behavior, * Study participant diagnosed with severe depression in the past 6 months prior to the Screening Visit. * Study participant has a history of psychiatric inpatient hospitalization within the past year before enrolling into the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Plasma bimekizumab concentrations at Week 16 | At Week 16 | Plasma samples will be collected prior to dosing for measurement of plasma concentrations of bimekizumab at the specified timepoint. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Exposure-adjusted incidence rate of Treatment- Emergent Adverse Events (TEAEs) during the Initial Treatment Period | From Baseline until end of the Initial Treatment Period (up to 16 weeks) | The TEAEs adjusted by duration of exposure to study treatment are scaled such that it provides an incidence rate per 100 patient-years. If a participant has multiple events, the time of exposure will be calculated to first occurrence of the AE being considered. If a participant has no events, the total time at risk will be used. An Adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to IMP. |
| Exposure-adjusted incidence rate of Serious TEAEs during the Initial Treatment Period | From Baseline until end of the Initial Treatment Period (up to 16 weeks) | The TEAEs adjusted by duration of exposure to study treatment are scaled such that it provides an incidence rate per 100 patient-years. If a participant has multiple events, the time of exposure will be calculated to first occurrence of the AE being considered. If a participant has no events, the total time at risk will be used. A SAE is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent disability/incapacity * Is a congenital anomaly/birth defect * Important medical events |
| Exposure-adjusted incidence rate of TEAEs leading to withdrawal during the Initial Treatment Period | From Baseline until end of the Initial Treatment Period (up to 16 weeks) | The TEAEs adjusted by duration of exposure to study treatment are scaled such that it provides an incidence rate per 100 patient-years. If a participant has multiple events, the time of exposure will be calculated to first occurrence of the AE being considered. If a participant has no events, the total time at risk will be used. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to IMP. |
| Exposure-adjusted incidence rate of Selected Safety Topics of Interest (including incidence of infections [serious, opportunistic, fungal, and TB], IBD, and injection site reactions) over the Initial Treatment Period | Up to Week 16 | Safety topics of interest for this study include events for which special monitoring will be for infections (serious, opportunistic, fungal, and tuberculosis \[TB\]), inflammatory bowel disease (IBD), and injection site reactions. |
| Mean Change from Baseline in vital signs (Systolic Blood Pressure and Diastolic Blood Pressure) at Week 16 | Baseline and Week 16 | Blood pressure (Systolic Blood Pressure and Diastolic Blood Pressure) will be measured in millimeters of mercury (mmHg). |
| Mean Change from Baseline in vital sign (Pulse rate) at Week 16 | Baseline and Week 16 | Pulse Rate will be measured in beats per minute (beats/min). |
| Mean Change from Baseline in Biochemistry Laboratory Analyses (glucose, potassium, sodium, calcium) at Weeks 4,12, and 16 | Baseline, Weeks 4, 12, and 16 | Glucose, potassium, sodium and calcium will be measured in millimoles per liter (mmol/L). |
| Mean Change from Baseline in Biochemistry Laboratory Analyses (total bilirubin and direct bilirubin, total protein, blood urea nitrogen, and creatinine) at Weeks 4,12, and 16 | Baseline, Weeks 4, 12, and 16 | Biochemistry parameters (total bilirubin and direct bilirubin, total protein, blood urea nitrogen \[BUN\], and creatinine) will be measured in micromols per liter (μmol/L). |
| Mean Change from Baseline in Biochemistry Laboratory Analyses (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase) at Weeks 4,12, and 16 | Baseline, Weeks 4, 12, and 16 | Biochemistry parameters (alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT) will be measured in units per liter (U/L). |
| Mean Change from Baseline in Hematology Laboratory Analyses (hemoglobin) at Weeks 4,12, and 16 | Baseline, Weeks 4, 12, and 16 | Hemoglobin will be measured in grams per liter (g/L). |
| Mean Change from Baseline in Hematology Laboratory Analyses (hematocrit) at Weeks 4,12, and 16 | Baseline, Weeks 4, 12, and 16 | Hematocrit will be measured in volume percentage (%) of red blood cells in blood. |
| Mean Change from Baseline in Hematology Laboratory Analyses (platelets, leukocytes, neutrophils, lymphocytes, eosinophils, basophils, and monocytes) at Weeks 4, 12, and 16 | Baseline, Weeks 4, 12, and 16 | Platelets, leukocytes, neutrophils, lymphocytes, eosinophils, basophils, and monocytes will be measured in number of blood cells per liter (10\^9/L) |
| Mean Change from Baseline in Hematology Laboratory Analyses (erythrocytes) | Baseline, Week 4, 12, and 16 | Erythrocytes will be measured in number of red blood cells per liter (10\^12/L). |
| Incidence rate for Positive, Negative, Missing Plasma Anti-Bimekizumab Antibodies at Baseline and Week 16 | Baseline and Week 16 | Positive, negative, and missing plasma anti-bimekizumab antibodies detection prior to and following IMP administration during the Initial Treatment Period. |
Countries
Germany, Poland, United States
Contacts
STUDY_DIRECTORUCB Cares
001 844 599 2273
Outcome results
None listed